In India, it was found that using a PCSK9 inhibitor, evolocumab 420 mg every month, combined with standard therapy in homozygous FH patients carrying impaired LDLR activity was ineffective in controlling plasma lipids or limiting the number of heart diseases. Here, LDLR is linked to familial hyperaldosteronism.